These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17679116)

  • 1. Prevention of contrast-induced nephropathy in high-risk patients with hemofiltration.
    Coca SG; Perazella MA
    Am J Med; 2007 Aug; 120(8):e9; author reply e11. PubMed ID: 17679116
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of contrast-induced nephropathy: an overview.
    Ellis JH; Cohan RH
    Radiol Clin North Am; 2009 Sep; 47(5):801-11, v. PubMed ID: 19744595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study.
    Shah SJ; Hsu CY
    Am J Med; 2004 Dec; 117(12):948-52. PubMed ID: 15629734
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing contrast nephropathy in catheter laboratory.
    Fung JW; Szeto CC; Yu CM
    Heart; 2007 Jun; 93(6):654-5. PubMed ID: 17502647
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter regarding article by Solomon et al, "Cardiac Angiography in REnally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease".
    Locatelli F
    Circulation; 2008 Feb; 117(7):e165; author reply e167. PubMed ID: 18285572
    [No Abstract]   [Full Text] [Related]  

  • 6. Contrast-induced nephropathy: prevention and management of high-risk patients.
    Caixeta A; Nikolsky E; Mehran R
    Indian Heart J; 2008; 60(6):524-31. PubMed ID: 19276490
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients.
    Marenzi G; Lauri G; Campodonico J; Marana I; Assanelli E; De Metrio M; Grazi M; Veglia F; Fabbiocchi F; Montorsi P; Bartorelli AL
    Am J Med; 2006 Feb; 119(2):155-62. PubMed ID: 16443418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Superiority of iodixanole vs hypoosmolar contrasts in the prevention of contrast-induced nephropathy in patients at risk: myth or reality?].
    Recio-Mayoral A
    Med Clin (Barc); 2010 Sep; 135(8):362-4. PubMed ID: 20557906
    [No Abstract]   [Full Text] [Related]  

  • 9. [The use of acetylcysteine for preventing contrast-induced nephropathy].
    Schaad N; Barghouth G
    Rev Med Suisse; 2005 Jun; 1(25):1693-6. PubMed ID: 16117036
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemofiltration and the prevention of radiocontrast-agent-induced nephropathy.
    Forman JP
    N Engl J Med; 2004 Feb; 350(8):836-8; author reply 836-8. PubMed ID: 14978836
    [No Abstract]   [Full Text] [Related]  

  • 11. Preventing nephropathy induced by contrast medium.
    Tepel M
    N Engl J Med; 2006 Apr; 354(17):1853-5; author reply 1853-5. PubMed ID: 16642596
    [No Abstract]   [Full Text] [Related]  

  • 12. Review of contrast-induced nephropathy and current use of N-acetylcysteine (NAC).
    Anwar M; Ledger S
    CANNT J; 2005; 15(1):33-8,quiz 38-9. PubMed ID: 15909775
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium bicarbonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy.
    Bouzas-Mosquera A; Recio-Mayoral A
    Am Heart J; 2008 Apr; 155(4):e31. PubMed ID: 18371455
    [No Abstract]   [Full Text] [Related]  

  • 14. Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients.
    van den Berk G; Tonino S; de Fijter C; Smit W; Schultz MJ
    Crit Care; 2005 Aug; 9(4):361-70. PubMed ID: 16137385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical inquiries. What interventions reduce the risk of contrast nephropathy for high-risk patients?
    Grossman PD; Burroughs M; Guthmann RA
    J Fam Pract; 2005 Apr; 54(4):365-7. PubMed ID: 15833230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
    Stenstrom DA; Muldoon LL; Armijo-Medina H; Watnick S; Doolittle ND; Kaufman JA; Peterson DR; Bubalo J; Neuwelt EA
    J Vasc Interv Radiol; 2008 Mar; 19(3):309-18. PubMed ID: 18295688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of hydration and acetylcysteine in the prevention of contrast-induced nephropathy: a potentially catastrophic complication of the percutaneous coronary interventions.
    Iyisoy A; Celik T; Yuksel UC; Bugan B; Isik E
    Int J Cardiol; 2009 May; 134(3):431-3; author reply 434. PubMed ID: 18501445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-induced nephropathy.
    Narang R; Sakhare M; Bahl VK
    Indian Heart J; 2004; 56(1):13-20. PubMed ID: 15129784
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy?
    Gonzales DA; Star RA; Kern SJ; Natanson C; Danner RL
    Ann Intern Med; 2008 Aug; 149(3):213-4; author reply 215-6. PubMed ID: 18678852
    [No Abstract]   [Full Text] [Related]  

  • 20. Contrast-induced kidney injury: focus on modifiable risk factors and prophylactic strategies.
    Kagan A; Sheikh-Hamad D
    Clin Cardiol; 2010 Feb; 33(2):62-6. PubMed ID: 20186983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.